258 related articles for article (PubMed ID: 37323173)
1. Comparative efficacy and safety of multitarget angiogenesis inhibitor combined with immune checkpoint inhibitor and nivolumab monotherapy as second-line or beyond for advanced lung adenocarcinoma in driver-negative patients: a retrospective comparative cohort study.
Yu L; Xu J; Qiao R; Zhong H; Brueckl WM; Zhong R
Transl Lung Cancer Res; 2023 May; 12(5):1108-1121. PubMed ID: 37323173
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of anlotinib combined with PD-1/PD-L1 inhibitors as second-line and subsequent therapy in advanced small-cell lung cancer.
Yu L; Xu J; Qiao R; Han B; Zhong H; Zhong R
Cancer Med; 2023 Mar; 12(5):5372-5383. PubMed ID: 36250532
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Anti-PD-1 Plus Anlotinib in Patients With Advanced Non-Small-Cell Lung Cancer After Previous Systemic Treatment Failure-A Retrospective Study.
Wang P; Fang X; Yin T; Tian H; Yu J; Teng F
Front Oncol; 2021; 11():628124. PubMed ID: 33791214
[TBL] [Abstract][Full Text] [Related]
4. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of anlotinib with and without EGFR-TKIs or immunotherapy in the treatment of elder patients with non-small-cell lung cancer: a retrospective study.
Wang W; Shao L; Xu Y; Song Z; Lou G; Zhang Y; Chen M
BMC Pulm Med; 2022 May; 22(1):179. PubMed ID: 35524294
[TBL] [Abstract][Full Text] [Related]
6. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
[TBL] [Abstract][Full Text] [Related]
7. A cohort study of the efficacy and safety of immune checkpoint inhibitors plus anlotinib versus immune checkpoint inhibitors alone as the treatment of advanced non-small cell lung cancer in the real world.
Shi Y; Ji M; Jiang Y; Yin R; Wang Z; Li H; Wang S; He K; Ma Y; Wang Z; Lu J; Shi M; Shen B; Zhou G; Leong TL; Wang X; Chen C; Feng J
Transl Lung Cancer Res; 2022 Jun; 11(6):1051-1068. PubMed ID: 35832459
[TBL] [Abstract][Full Text] [Related]
8. Multi-target angiogenesis inhibitor combined with PD-1 inhibitors may benefit advanced non-small cell lung cancer patients in late line after failure of EGFR-TKI therapy.
Yu L; Hu Y; Xu J; Qiao R; Zhong H; Han B; Xia J; Zhong R
Int J Cancer; 2023 Aug; 153(3):635-643. PubMed ID: 37078587
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of immune checkpoint inhibitors plus recombinant human endostatin therapy as second-line treatment in advanced non-small-cell lung cancer with negative driver gene: a pilot study.
Yang B; Li Y; Deng J; Yang H; Sun X
Front Oncol; 2023; 13():1210267. PubMed ID: 38023216
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy for patients with advanced non-small cell lung cancer harboring oncogenic driver alterations other than
Tian T; Li Y; Li J; Xu H; Fan H; Zhu J; Wang Y; Peng F; Gong Y; Du Y; Yan X; He X; Cali Daylan AE; Pircher A; Neibart SS; Okuma Y; Hong MH; Huang M; Lu Y
Transl Lung Cancer Res; 2024 Apr; 13(4):861-874. PubMed ID: 38736501
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of anlotinib plus programmed death-1 blockade versus anlotinib monotherapy as second or further-line treatment in advanced esophageal squamous cell carcinoma: A retrospective study.
Liu Y; Ge Q; Xu S; Li K; Liu Y
Front Oncol; 2022; 12():942678. PubMed ID: 36059654
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of immune checkpoint inhibitor monotherapy in pretreated elderly patients with non-small cell lung cancer.
Yamaguchi O; Imai H; Minemura H; Suzuki K; Wasamoto S; Umeda Y; Osaki T; Kasahara N; Uchino J; Sugiyama T; Ishihara S; Ishii H; Naruse I; Mori K; Kotake M; Kanazawa K; Minato K; Kagamu H; Kaira K
Cancer Chemother Pharmacol; 2020 Apr; 85(4):761-771. PubMed ID: 32193618
[TBL] [Abstract][Full Text] [Related]
13. The efficacy and safety of immune checkpoint inhibitors combined with chemotherapy or anti-angiogenic therapy as a second-line or later treatment option for advanced non-small cell lung cancer: a retrospective comparative cohort study.
Chen B; Wang J; Pu X; Li J; Wang Q; Liu L; Xu Y; Xu L; Kong Y; Li K; Xu F; Liang S; Cardona AF; Wu L
Transl Lung Cancer Res; 2022 Oct; 11(10):2111-2124. PubMed ID: 36386462
[TBL] [Abstract][Full Text] [Related]
14. Anlotinib combined with PD-1 blockade for the treatment of lung cancer: a real-world retrospective study in China.
Zhang X; Zeng L; Li Y; Xu Q; Yang H; Lizaso A; Mao X; Jin R; Zeng Y; Li Q; Wang J; Li Y; Zhang Y; Yang N
Cancer Immunol Immunother; 2021 Sep; 70(9):2517-2528. PubMed ID: 33566148
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety analysis of immune checkpoint inhibitor rechallenge therapy in locally advanced and advanced non-small cell lung cancer: a retrospective study.
Yan X; Zhao L; Wu F; Shen B; Zhou G; Feng J; Yue C; Zhu J; Yu S
J Thorac Dis; 2024 Mar; 16(3):1787-1803. PubMed ID: 38617775
[TBL] [Abstract][Full Text] [Related]
16. [Comparison of efficacy and safety between domestic immune checkpoint inhibitors and pembrolizumab in the treatment of driver gene-negative advanced non-small cell lung cancer].
Chen YQ; Zhang YD; Yan H; Qin HY; Huang Z; Zhang X; Xiang SQ; Hu XQ; Wu F; Zhang YC; Zeng L; Yang N
Zhonghua Yi Xue Za Zhi; 2024 Jan; 104(4):282-289. PubMed ID: 38246773
[No Abstract] [Full Text] [Related]
17. The Real-world Therapeutic Analysis of First-line Immunotherapy in Chinese Patients with Drive Gene Positive for Advanced Non-Small Cell Lung Cancer.
Liu L; Li F; Zhao J; Zhuo X; Lai J; Wang J; Jiang F; Xu W; Luan F; Lin X; Yang S; Fu G
J Cancer; 2023; 14(6):952-965. PubMed ID: 37151388
[No Abstract] [Full Text] [Related]
18. Immunotherapy as second-line treatment and beyond for non-small cell lung cancer in a single center of China: Outcomes, toxicities, and clinical predictive factors from a real-world retrospective analysis.
Chen M; Li Q; Xu Y; Zhao J; Zhang L; Wei L; Zhong W; Wang M
Thorac Cancer; 2020 Jul; 11(7):1955-1962. PubMed ID: 32468726
[TBL] [Abstract][Full Text] [Related]
19. Immune checkpoint inhibitor (ICI)-based treatment beyond progression with prior immunotherapy in patients with stage IV non-small cell lung cancer: a retrospective study.
Tian T; Yu M; Yu Y; Wang K; Tian P; Luo Z; Ding Z; Wang Y; Gong Y; Zhu J; Zou B; Sio TT; Alves A; Liu Y; Huang M; Lu Y
Transl Lung Cancer Res; 2022 Jun; 11(6):1027-1037. PubMed ID: 35832458
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer (NSCLC): a systematic literature review.
Wagner G; Stollenwerk HK; Klerings I; Pecherstorfer M; Gartlehner G; Singer J
Oncoimmunology; 2020 Jun; 9(1):1774314. PubMed ID: 32923134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
